참고문헌
- Stangier J, Su CA, Roth W. Pharmacokinetics of Orally and Intravenously Administered Telmisartan in Healthy Young and Elderly Volunteers and in Hypertensive Patients. J int Med Res 2000; 28: 149-67. https://doi.org/10.1177/147323000002800401
- Wienen W, Entzeroth M, Van Meel JCA, et al. A Review on Telmisartan: A Novel, Long-Acting Angiotensin IIReceptor Antagonist. Cardiovasc Drug Rev 2000; 18: 127-54.
- Ren S, Zeng J, Mei Y, et al. Discovery and Characterization of Novel, Potent, and Selective Cytochrome P450 2J2 Inhibitors. Drug Metab Dispos 2013; 41: 60-71. https://doi.org/10.1124/dmd.112.048264
- Stangier J, Schmid J, Trck D, et al. Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J Clin Pharmacol 2000; 40: 1312-22.
- Lennerns H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003; 42: 1141-60. https://doi.org/10.2165/00003088-200342130-00005
- Kearney AS, Crawford LF, Mehta SC, et al. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharm Res 1993; 10: 1461-5. https://doi.org/10.1023/A:1018923325359
- Grube M, Kck K, Oswald S, et al. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther 2006; 80: 607-20. https://doi.org/10.1016/j.clpt.2006.09.010
- Kalliokoski A. and Niemi M. REVIEW: Impact of OATP transporters on pharmacokinetics Br J Pharmacol 2009; 158: 693-705. https://doi.org/10.1111/j.1476-5381.2009.00430.x
- Ishiguro N, Maeda K, Kishimoto W, et al. Predominant contribution of OATP1b3 to the hepatic uptake of telmisartan, An angiotensin II receptor antagonist, in humans. Drug Metab Dispos 2006; 34: 1109-15. https://doi.org/10.1124/dmd.105.009175
- Macwan JS, Ionita IA, Dostalek M, et al. Development and validation of a sensitive, simple, and rapid method for simultaneous quantitation of atorvastatin and its acid and lactone metabolites by liquid chromatography-tandem mass spectrometry(LC-MS/MS) Anal Bioanal Chem 2011; 400: 423-33. https://doi.org/10.1007/s00216-011-4804-y
- Herv F, Urien S, Albengres E, et al. Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding. Clin Pharmacokinet 1944; 26: 44-58.
- Vats R, Varanasi KV, Arla R, et al. Effect of multidose cilostazol on pharmacokinetic and lipid profile of atorvastatin in male Wistar rats. J Pharm Pharmacol 2012; 64: 1638-45. https://doi.org/10.1111/j.2042-7158.2012.01542.x
- Karlgren M, Vildhede A, Norinder U, et al. Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug-Drug Interactions. J Med Chem 2012; 55: 4740-63. https://doi.org/10.1021/jm300212s
- Lins RL, Matthys KE, Verpooten GA, et al. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol Dial Transplant 2003; 18: 967-76. https://doi.org/10.1093/ndt/gfg048
- Lau YY, Okochi H, Huang Y, et al. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos 2006; 34: 1175-81. https://doi.org/10.1124/dmd.105.009076
- DeGorter MK, Ho RH, Leake BF, et al. Interaction of three regiospecific amino acid residues is required for OATP1B1 gain of OATP1B3 substrate specificity. Mol Pharm 2012; 9: 986-95. https://doi.org/10.1021/mp200629s
- Kalliokoski A, Backman JT, Kurkinen KJ, et al. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin Pharmacol Ther 2008; 84: 488-96. https://doi.org/10.1038/clpt.2008.74
- Hermann M, Asberg A, Christensen H, et al. Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. Clin Pharmacol Ther 2004; 76: 388-91. https://doi.org/10.1016/j.clpt.2004.07.008
- Lemahieu WP, Hermann M, Asberg A, et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 2005; 5: 2236-43. https://doi.org/10.1111/j.1600-6143.2005.01005.x
- Backman JT, Luurila H, Neuvonen M, et al. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 2005; 78: 154-67. https://doi.org/10.1016/j.clpt.2005.04.007
- Lau YY, Huang Y, Frassetto L, et al. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 2007; 81: 194-204. https://doi.org/10.1038/sj.clpt.6100038
- Yoon H, Osun B. Drug interaction of warfarin with simvastatin/gemfibrozil: high levels of ALT/AST, rhabdomyolysis and acute renal failure. Kor J Clin Pharm 2011; 21: 270-5.
- Choi MK, Bang JS, Lee YJ. Patterns of over-the-counter drug use and interactions between over-the counter drugs and prescription drugs in adults visiting a community pharmacy. Kor J Clin Pharm 2013; 23: 49-56.
- Miura M, Satoh S, Kagaya H, et al. Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. J Clin Pharm Ther 2009; 34: 683-92. https://doi.org/10.1111/j.1365-2710.2009.01053.x
- Kataoka M, Takashima T, Shingaki T, et al. Dynamic analysis of GI absorption and hepatic distribution processes of telmisartan in rats using positron emission tomography. Pharm Res 2012; 29: 2419-31. https://doi.org/10.1007/s11095-012-0768-7
- Hao K, Chen YC, Cao YG, et al. Pharmacokineticpharmacodynamic modeling of telmisartan using an indirect response model in spontaneously hypertensive rats. Acta Pharmacol Sin 2007; 28: 738-48. https://doi.org/10.1111/j.1745-7254.2007.00556.x